2Pauwels R, Lofdahl C, Laitinen L, et al. Long term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med, 1999,340 ( 25 ) : 1948.
3Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A rondomize controlled trial. Lancet, 1999,353 (9167 ) : 1819.
4The Lung Health Research Group. Effect of inhaler triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med,2000,343(26) :1902.
5Burge P, Calverley P,Jones P, et al. Randomized, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease:the ISOLDE trial. Brit Med J ,2000,320 (7245) :1297.
6Sin DD, Tu JV, Inhaled corticosteruids and risk and mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med,2001,164(4) :580.
3Pauwels R, Lofdahl C, Laitinen L, et al. Long term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med[J]. 1999,340(25):1948.
4Vestbo J,Sorensen T,Lange P,et al. Long - term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomized controlled trial [ J ]. Lancet, 1999,353(9167) :1819.
5The Lung Health Research Group. Effect of inhaler triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease[J]. N Engl J Med,2000,3.43 (26) :1902.
6Burge P,Calverley P, Jones P, et al. Randomized,double blind,placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial [J]. Brit Med J,2000,320(7245) :1297.
7Sin DD, Tu JV. Inhaled corticosteroids and risk and mortality and readmission in elderly patients with chronic obstructive pulmonary disease[ J]. Am J Respir Crit Care Med ,2001,164(4) :580.
8GOLD Executive Committee[DB/OL].Guidelines:Global Strategy for Diagnosis,Management,and Prevention of COPD,November 2006[2006-11-18].http://www.goldcopd.com/Guidelineitem.asp? l1 =2-12 = 1&intId =989.
9Celli BR,MacNee W,Committee members.Standard for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper.Eur Respir J,2004,23:932-946.
10Celli BR,Cote CG,Marin JM,ct al.The body mass index,airflow obstruction,dyspnea and exercise capacity index in chronic obstructive pulmonary disease.N Engl J Med,2004,350:1005-1012.
6Lipworth BJ.Phosphodiesterase-4 inhibitors for &sthm& and chronic obstructive pulmon&ry dise&se[J]. L&ncet, 2005,565:167-175.
7Tashkin DP,Oelli B,Senn S,et aI.A 4-year trial of tiotrop'ium in chronic obstructive pulmonary disease[J].N Engl J Med,2008,359:1543- 1554.
8CosioBG,LglesiasA,l oisA,et aI.Low-dose theophylline enh&nces the &nti-infiam-m&tory effeets of steroids during exacerbation of COPD[J]. Thorax, 2009,64. 424-429.
9Cola C,Almeida M,Li D,et aI.FLegulatory role of endothelium in the expression of genes ffectJng arteria calcification[J].BJochem Biophys P es Commun, 2004,320(2) : 424-427.
10Salpeter SE Buckley NS.Systematic review of clinical outcomes in chronic obstructive pulmonary disease,beta-agonistuse comparedwith anticholinergics and inhaled corticosteroids[J].Clin P, ev Allergy ].mmunol, 2006,51 : 219-230.
